HC Wainwright Weighs in on Gracell Biotechnologies Inc.’s Q1 2023 Earnings (NASDAQ:GRCL)

Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Gracell Biotechnologies in a research report issued to clients and investors on Monday, March 13th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Gracell Biotechnologies’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Gracell Biotechnologies’ Q2 2023 earnings at ($0.39) EPS, Q4 2023 earnings at ($0.47) EPS, FY2023 earnings at ($1.62) EPS, FY2024 earnings at ($1.53) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.00) EPS and FY2027 earnings at ($0.46) EPS.

Gracell Biotechnologies Stock Performance

Gracell Biotechnologies stock opened at $2.00 on Thursday. The company has a market cap of $135.36 million, a price-to-earnings ratio of -1.48 and a beta of -1.84. Gracell Biotechnologies has a 12 month low of $1.68 and a 12 month high of $5.69. The company has a debt-to-equity ratio of 0.03, a current ratio of 6.77 and a quick ratio of 6.77. The stock’s 50-day moving average is $2.11 and its 200-day moving average is $2.60.

Institutional Trading of Gracell Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of GRCL. EcoR1 Capital LLC grew its stake in Gracell Biotechnologies by 74.0% during the fourth quarter. EcoR1 Capital LLC now owns 3,343,202 shares of the company’s stock worth $7,689,000 after buying an additional 1,421,892 shares during the period. Capital Group International Inc. CA boosted its position in Gracell Biotechnologies by 33.4% during the 1st quarter. Capital Group International Inc. CA now owns 2,335,476 shares of the company’s stock worth $5,442,000 after purchasing an additional 584,769 shares during the period. BlackRock Inc. boosted its position in Gracell Biotechnologies by 18.6% during the 1st quarter. BlackRock Inc. now owns 924,631 shares of the company’s stock worth $2,154,000 after purchasing an additional 144,940 shares during the period. Schonfeld Strategic Advisors LLC increased its holdings in Gracell Biotechnologies by 38.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 374,841 shares of the company’s stock valued at $862,000 after purchasing an additional 104,668 shares in the last quarter. Finally, Capital International Sarl lifted its stake in shares of Gracell Biotechnologies by 3.9% during the first quarter. Capital International Sarl now owns 228,149 shares of the company’s stock worth $532,000 after purchasing an additional 8,508 shares in the last quarter. Institutional investors and hedge funds own 45.10% of the company’s stock.

Gracell Biotechnologies Company Profile

(Get Rating)

Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.